The Psychedelic Science conference, co-hosted by the Beckley Foundation, brought together researchers from around the world to discuss research, clinical trials, and medical discoveries involving psychedelic substances. Amanda Feilding presented the results of the Beckley Foundation research programme, including our recent investigations into psilocybin and MDMA.
MDMA
Since its inception in 1998, the Beckley Foundation has focused on using psychoactive substances as tools to alter cognitive function. By studying the impacts psychoactive substances, like MDMA, have on the brain, we gain a clearer understanding of brain flow, neural activity, and how the mind works.
The Beckley Foundation brain-imaging studies using MDMA (ecstasy) have provided a neurophysiological explanation of why MDMA can be a valuable aid in psychotherapy. Most notable, the Beckley Foundation’s groundbreaking research showed that MDMA can be help war veterans suffering from post-traumatic stress disorder (PTSD). This research sheds light on the mechanisms by which MDMA allows traumatic experiences to be recalled, and dealt with, without an overwhelming emotional response. This, and a complete list of Beckley Foundation studies involving MDMA can be accessed by clicking here.
